

REPROS THERAPEUTICS INC.  
Form 8-K  
July 15, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report  
(Date of earliest event reported): July 14, 2008  
Repros Therapeutics Inc.  
(Exact name of registrant as specified in its charter)**

**Delaware**

**001-15281**

**76-0233274**

**(State or other jurisdiction of  
incorporation or organization)**

**(Commission File Number)**

**(I.R.S. Employer Identification  
No.)**

**2408 Timberloch Place, Suite B-7  
The Woodlands, Texas 77380**

**(Address of principal  
executive offices  
and zip code)**

**(281) 719-3400**

**(Registrant's telephone  
number, including area  
code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure**

Repros Therapeutics Inc. (the Company ) announced today that it will host an analyst meeting for the financial community beginning at 10:00 a.m. Eastern Time on Thursday, July 24, 2008 in New York City. The event, which is by invitation only, will focus on the Company s clinical drug candidate Proelle®. There will be a live video webcast of the event, and it will be subsequently archived for at least one month on the Company s website.

A copy of the Company s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

**Item 9.01. Financial Statements and Exhibits**

d. Exhibit

Exhibit

Number	Description
99.1	Press Release dated July 14, 2008.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: July 14, 2008

By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.  
Vice President, Business Development and  
Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press Release dated July 14, 2008.